Objective: Hypopituitary GH-deficient patients have an increased cardiovascular mortality and GH replacement in this population has resulted in considerable therapeutic benefit. GH replacement involves administration of a potentially mitogenic substance to patients with a previous or residual pituitary tumour. Our objective was to evaluate whether GH replacement results in an increase in the size of pituitary tumours. Methods: This was a non-randomised observational study on patients recruited from the endocrine clinic. All subjects had GH deficiency, proven on an insulin tolerance test and were divided into those who were or were not receiving long-term GH replacement. Comparison of change in pituitary size was made with interval radiological imaging of the pituitary. Results: Seventy-five patients (40 men and 35 women) were in the study, 47 were on long-term GH replacement and there were 28 controls. The average length of treatment for the treated group was 3.6 patient years. Thirty-nine patients in the treated group had at least 2 years of GH treatment between imaging studies of the pituitary. Two patients in the treated group had an increase in pituitary size (non-functioning adenomas) and two in the control group (one functioning and one nonfunctioning adenoma adenoma). None of these four patients required further treatment. There was no statistically significant difference between the two groups. Conclusion: Using a representative cohort of hypopituitary patients attending an endocrine clinic, GH replacement was not associated with an increased pituitary tumour recurrence rate. Although the results are not conclusive, in the period of observation GH had little adverse effect but longer studies are required to be certain.
Introduction
Growth hormone (GH) replacement in adult GHdeficient patients has been studied extensively in the last 10 years. All studies have reported considerable therapeutic benefit with improvements in body composition, lipid profile, cardiovascular risk, exercise performance and quality of life (1 -6). GH has now been given regulatory approval for adults in many countries including Europe and the USA. While safety in the short-lived clinical trials is without doubt, there are unanswered questions in the long term. Much is made of the increased cardiovascular mortality in hypopituitary GH-deficient patients reported in two well-conducted epidemiological studies from Sweden (7, 8) . This, coupled with the finding of premature atherosclerosis (9) , unfavourable lipid (10) and cardiovascular risk profile (11) together with favourable changes on GH replacement (5, 6, 11), has prompted some to suggest that GH replacement may lead to a lessening of the cardiovascular mortality in this patient group. However, there are concerns that GH replacement involves administration of an anabolic and potentially mitogenic substance to a patient group that contains many with previous or residual pituitary tumours. GH excess has been associated with an increased prevalence of pre-malignant colonic polyps (12) but it is less certain whether there is an increased prevalence of cancer (13) . Although reports concerning GH excess cannot be extrapolated to GH replacement of deficient adults it is interesting to note that, although cardiovascular mortality was increased in hypopituitary GH-deficient adults, cancer deaths were reduced (7, 8) .
Most of the pharmaceutical companies marketing GH have set in place elaborate surveillance schemes without untreated control groups. Thus comparisons with historically reported series of pituitary recurrence rates will have to be made which may not be appropriate. Our centre has some of the adult GH-deficient patients who have been treated the longest with GH replacement. We have compared two similarly matched groups of patients differing only in whether they were being treated with GH. Pituitary recurrence or enlargement was assessed in a blinded control study.
Materials and methods
This study was performed as a non-randomised observational study on patients recruited from those attending the Pituitary Endocrine Clinic. All subjects had GH deficiency, proven on an insulin tolerance test (ITT) with nadir plasma glucose , 2.2 mmol/l. GH deficiency was defined as a peak GH level during an ITT of 6 mU/l (2 mg /l). All patients included in the study had had at least one imaging procedure (magnetic resonance imaging (MRI) or computed tomography (CT)) of the pituitary following their surgery or radiotherapy. Patients who had undergone only one imaging procedure of the pituitary gland following treatment were recalled for repeat MRI scans. One hundred and thirty-seven scans were performed with a Philips 1.5T Gyroscan S15/ACS (Philips, Eindhoven, The Netherlands) or a Siemens 1.0T or 1.5T Magnetom (Siemens, Erlangen, Germany). Seventeen of the earlier scans were performed on a Siemens Somatom DRH CT scanner with 2 mm slices taken through the pituitary with reformat in the coronal and sagittal planes. Patients who had only had imaging studies of the pituitary gland prior to definitive surgery/radiotherapy were excluded, as comparative studies between pre-treatment and posttreatment scans would be invalid. The remaining group was divided into patients who were on longterm GH replacement (treated) and those who were not (controls). The control group consisted of patients who were unable to obtain GH prescriptions from their primary care physicians or had been referred to our unit for consideration for GH replacement. Imaging of the pituitary was performed either to act as a followup scan in those patients with previous studies who then entered the control arm, or as a baseline for patients about to enter the treatment arm of the study. Patient details are shown in Table 1 .
The scans were reviewed independently by two consultant radiologists, blinded to therapy. The volume of the pituitary tissue between consecutive studies was graded as unchanged, larger or smaller. The amount of residual tissue seen on the initial scan was also documented. Any scan reports showing a difference of opinion were reviewed jointly by the two consultants and a consensus opinion was reached.
An analysis of the data was performed using ordered logistic regression to look at the odds of a bad outcome (increase in pituitary size). As an empty sella is less likely to demonstrate tumour regrowth the regression analysis was adjusted for tumour size on the initial scan to avoid bias. Relative risks were also analysed for each group and a x 2 test assuming no difference between the two groups was applied.
Results
A total of 75 patients was entered for the study. Of these, 47 were on long-term GH replacement therapy and the remaining 28 acted as controls. The average dose and length of treatment for the treated group was 0.029 IU/kg per day (range 0.001 -0.075) and 3.6 patient years (range 197 days -3947 days, median 3.4 years) respectively, giving a total of 169 patient years. Thirty-nine patients in the treated group had at least 2 years of GH treatment between imaging studies of the pituitary. Imaging was performed, on average, 288 days prior to commencing GH therapy. The average time-interval between imaging studies in the control group was 3.4 years. The average age in the treated group was 49 years (20 -69, 22 men and 25 women) compared with 52 years (31 -73, 18 men and 10 women) in the control group. Both groups showed a mixed aetiology for GH deficiency (Table 1) and for other replacement therapy ( Table 2 ). The average time-interval between surgery/ radiotherapy and the baseline imaging study of the pituitary was 7.0 years for the GH-treated group and 6.2 years for the control group.
There was disparity in the radiologist's report in four patients in the control group and ten in the treated group before a consensus opinion was reached. In the (Table 3) with recurrences occurring in one patient with a nonfunctioning adenoma and another in a patient with a functioning adenoma. The details of the patients showing an increase in pituitary tissue are documented in Table 4 . None of the four patients who showed an increase in size in their pituitary has required further treatment.
The risk ratio for patients on GH therapy compared with controls is 0.596 (confidence intervals 0.0888 -3.99). A x 2 test to one degree of freedom showed no difference between the two groups (xð1Þ ¼ 0:29; P ¼ 0:5904). Ordered logistic regression, adjusted for tumour size on initial scan, showed GH had no apparent effect on tumour growth (odds ratio 1.02: 95% confidence intervals 0.31 -3.32).
Discussion
Pituitary adenomas are slowly proliferating benign clonal tumours (14) . The aim of treatment is the control of tumour cell proliferation by surgery, radiotherapy and medical treatment, coupled with replacement of hormone deficiency. Until recently, GH was not considered a necessary replacement therapy. GH replacement leads to therapeutic benefit with changes in body composition, improvements in cardiac and exercise performance, favourable alteration of cardiovascular risk factors and improvements in quality of life (1-6). However, many regulatory authorities have voiced concerns about the anabolic and mitogenic potential of GH and its administration to patients with previous or residual pituitary tumours. The main finding of the present study was that GH replacement does not appear to be associated with an increased rate of pituitary tumour recurrence. Although these represent some of the longest observations available at present, further long-term studies are necessary to be certain that GH replacement is safe. The recurrence rates described in the present study are similar to other reported series. Bradley et al. (15) reviewed 42 patients with non-functioning pituitary adenomas who had been imaged before and at least 2 years after transphenoidal surgery. Eight patients were deemed to have had shown regrowth. Rauhut et al. (16) reported recurrence rates in a study of 210 patients and, depending on the surgical approach, total or subtotal removal, the recurrence rate varied from 10.4 to 35%. In contrast, Ebersold et al. (17) found a lower recurrence rate when reviewing the results of 100 transphenoidal surgery excisions of pituitary adenomas and found only ten patients who demonstrated radiological recurrence between 48 and 100 months follow-up. The most extensive review of radiotherapy either as sole treatment or in combination with surgery has been reported by Brada et al. (18) . Of a total of 411 patients with pituitary adenomas who had radiotherapy treatment, 73 had radiotherapy alone and 338 had it combined with surgery. The patients had a mixed aetiology (252 clinically non-secreting, 131 hormone secreting and 28 were indefinable). Only 25 patients (6.1%) had tumour progression. Thus, from the reported series (14) (15) (16) (17) (18) , there are large differences in tumour recurrence rates which largely depend on case mix, patient population, size of the original tumour, technique of surgery and whether radiotherapy was given. These illustrate the difficulty that surveillance studies will have in comparing current patients on GH replacement to controls from historical series and emphasise the importance of the current controlled study.
There is some evidence that GH excess in the form of acromegaly may be associated with colonic polyps and a theoretical increased chance of colonic cancer (12, 19, 20) . However, survival studies suggest that although there appears to be a trend for increased cancer, colonic cancer is not particularly increased (13) . It is wrong, however, to compare GH excess with GH replacement therapy that is attempting to be 'physiological'. The current initiating doses of GH are considerably lower than was used in the original studies and aim to keep GH-dependent variables such as insulin-like growth factor-I well within the normal range. It is interesting to note that our patients who are amongst the longest treated were exposed to much higher doses of GH initially before our greater understanding led to reductions (1 -6) and, despite this, no difference in recurrence rate was seen. Additional supportive evidence suggesting that physiological levels of GH have little effect on tumour recurrence comes from the numerous previously reported large series of pituitary adenomas. No difference in recurrence rates was seen in those patients rendered pan-hypopituitary compared to those not, who presumably had either normal or near normal GH secretion (15) (16) (17) (18) .
Limitations in our study include the few comparative imaging studies that were performed between CT and MRI. CT scans are less precise for assessing pituitary mass volume but these comparisons occurred in those patients with the longest treatment duration and who were recruited into the study prior to the ready availability of MRI. Using a logistic regression analysis adjusted for tumour size on the initial scan, we were able to avoid bias towards lack of regrowth in patients with small pituitary volumes. Patients with empty sellas were in fact the only category in which 100% of patients showed no change. In addition, the frequencies of post-operative radiation also differed in the two groups: 16/47 (34%) in the treated group and 21/27 (78%) in the control group. Irradiation may decrease the rate of tumour growth, which would bias towards a greater recurrence rate in the GH-treated group. Although our study showed no difference in recurrence between the two groups, there was no statistical significance. Our control group demonstrated a recurrence rate of 7% (2/28). If we were interested in a possible doubling of recurrence rate to 14% as a result of GH replacement, a study would need 328 patients in each group to have a four in five chance (80% power) to demonstrate an effect at the 5% significance level. This is clearly not feasible in a single centre.
In summary, in the current controlled study using a representative cohort of hypopituitary patients attending an endocrine clinic, GH replacement was not associated with an increased pituitary tumour recurrence rate. Although the results are not conclusive, the confidence intervals are suggestive that in the period of observation GH had little adverse effect but longer studies are required to be certain. 
